Geographic variation in the second-line treatment of non-small cell lung cancer

Medicine and Dentistry

• Treatment of Non-Small Cell Lung Cancer 100%
• Diseases 100%
• Clinical Trial 33%
• Non Small Cell Lung Cancer 33%
• Epidermal Growth Factor Receptor Kinase Inhibitor 33%
• Erlotinib 33%
• Gefitinib 33%
• Patient Experience 33%
• Drug Toxicity 33%
• Chemotherapy Agent 33%
• Cytotoxic Chemotherapy 33%
• Health Care Economics 33%
• Interstitial Lung Disease 33%
• Chemotherapy 33%
• Treatment Modality 33%
• Platinum 33%
• Ethnic Difference 33%
• Drug Activity 33%
• Drug Metabolism 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Diseases 100%
• Chemotherapy Agent 33%
• Clinical Trial 33%
• Cytotoxic Chemotherapy 33%
• Gefitinib 33%
• Erlotinib 33%
• Epidermal Growth Factor Receptor Kinase Inhibitor 33%
• Interstitial Lung Disease 33%
• Chemotherapy Regimen 33%
• Platinum 33%
• Drug Metabolism 33%